Comparing WTP Values of Different Types of QALY Gain Elicited from the General Public

• Published in: Health economics 2015-03, Vol.24 (3), p.280-293
• Main Authors: Pennington, Mark, Baker, Rachel, Brouwer, Werner, Mason, Helen, Hansen, Dorte Gyrd, Robinson, Angela, Donaldson, Cam
• Format: Article
• Language: English
• Subjects: contingent valuation; Cost-Benefit Analysis; Decision Making; Demography; Europe; EuroVaQ; Financing, Personal - statistics & numerical data; Health care expenditures; Health economics; Humans; Models, Econometric; Patient Acceptance of Health Care - psychology; Patient Acceptance of Health Care - statistics & numerical data; Quality of Life; Quality-Adjusted Life Years; Studies; Surveys and Questionnaires; Valuation methods; Willingness to pay
• ISSN: 1057-9230; 1099-1050
• DOI: 10.1002/hec.3018

Background The appropriate thresholds for decisions on the cost‐effectiveness of medical interventions remain controversial, especially in ‘end‐of‐life’ situations. Evidence of the values placed on different types of health gain by the general public is limited. Methods Across nine European countries, 17 657 people were presented with different hypothetical health scenarios each involving a gain of one quality adjusted life year (QALY) and asked about their willingness to pay (WTP) for that gain. The questions included quality of life (QoL) enhancing and life extending health gains, and a scenario where respondents faced imminent, premature death. Results The mean WTP values for a one‐QALY gain composed of QoL improvements were modest (PPP$11 000). When comparing QALY gains obtained in the near future, the valuation of life extension exceeded the valuation of QoL enhancing gains (mean WTP PPP$19 000 for a scenario in which a coma is avoided). The mean WTP values were higher still when respondents faced imminent, premature death (PPP$29 000). Conclusions Evidence from the largest survey on the value of health gains by the general public indicated a higher value for life extending gains compared with QoL enhancing gains. A further modest premium may be indicated for life extension when facing imminent, premature death. Copyright © 2013 John Wiley & Sons, Ltd.